The lead investigator touted the benefits of subcutaneous administration of daratumumab in relapsed multiple myeloma (MM) during a presentation on practice-changing results ahead of the American ...
"The continued expansion of DARZALEX delivered subcutaneously with ENHANZE into additional settings highlights its status as a cornerstone of therapy for multiple myeloma," said Dr. Helen Torley, ...
NEW YORK (Reuters Health) - Subcutaneous daratumumab could offer an effective and more convenient alternative to the intravenous formulation for patients with relapsed or refractory multiple myeloma, ...
Copenhagen, Denmark; April 30, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...
Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...
“Importantly, subcutaneous daratumumab demonstrated comparable efficacy with the existing IV formulation, reduced the rate of infusion-related reactions and significantly shortened the time it takes ...
Please provide your email address to receive an email when new articles are posted on . A subcutaneous formulation of daratumumab exhibited similar pharmacokinetics as the standard IV formulation ...
Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results